Sign in
MREO Stock Price, Chart, Stats & News
Mereo BioPharma Group plc
Save
49.39M
Market cap
–
Current P/E
–
Forward P/E
MREO chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 73.20% |
Operating margin | -8100.28% |
Pretax margin | -8766.04% |
Net margin | -8375.60% |
Effective tax rate | 1.08% |
ROA | -91.20% |
ROE | -83.02% |
D/E | 0.00x |
Interest coverage ratio | -158.96x |
MREO valuation
P/E | – |
P/S | 105.06x |
P/B | 1.28x |
P/CF | -1.69x |
P/FCF | -1.68x |
P/OCF | -1.69x |
PEG | 3.30x |
EV multiple | -2.37x |
About
Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor, is presently undergoing Phase 1b clinical investigation for tumor treatment.
Similar securities
Based on sector and market capitalization
Report issue